Avastin Biosimilar Phase III Data Will Support Extrapolation, Amgen Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Amgen and Allergan reported positive Phase III data for a biosimilar version of Roche’s blockbuster cancer drug Avastin in lung cancer, and are hopeful the data will support extrapolation to Avastin’s many indications.